INTRODUCTION
There are two autosomal dominant inherited disorders that share the name ''neurofibromatosis.'' Neurofibromatosis 1 (NF1), also called von Recklinghausen's neurofibromatosis, affects approximately 1 in 3500 individuals or over 100,000 people in the United States (Riccardi, 1991) , while neurofibromatosis 2 (NF2), formerly termed bilateral acoustic neurofibromatosis or central neurofibromatosis (Martuza and Eldridge, 1988) , is a disorder affecting 1 in 35,000 individuals. The gene for neurofibromatosis 1 has been identified on the long arm of chromosome 17 and encodes a protein that functions as a negative growth regulator (Cawthon et al., 1990; Viskochil et al., 1990; Wallace et al., 1990; Basu et al., 1992; DeClue et al., 1992) . Similarly, the NF2 gene product also functions as a negative growth regulator. Clinical features of NF1 include pigmented skin macules (café au lait spots), skin-fold freckling, hamartomas of the iris (Lisch nodules), and multiple neurofibromas. Individuals affected with NF1 may also present with optic pathway gliomas, macrocephaly, neurologic or cognitive impairment, or abnormalities of the skeleton (Gutmann and Collins, 1995) . Individuals affected with NF2 display increased frequency of meningiomas, schwannomas, and astrocytomas. Pigmentary abnormalities, macrocephaly, neurologic or cognitive impairment, or bony abnormalities are not features of NF2 (Evans et al., 1992) .
NEUROFIBROMATOSIS 2: CLINICAL FEATURES
The first probable case of NF2 was reported by Wishart in 1820. This patient had multiple intracranial tumors without the cutaneous features of NF1 and was therefore quite different from those patients reported by von Recklinghausen in 1882. Unfortunately, following von Recklinghausen's report, subsequent authors described cases of NF1 with intracranial tumors and NF2 with cutaneous features (Henschen, 1915; Cushing, 1917) . For this reason, the two conditions were grouped together and collectively called ''multiple neurofibromatosis.'' In 1930, Gardner and Frazier reported a large family with neurofibromatosis and suggested that bilateral vestibular schwannomas represented a separate form of neurofibromatosis (Gardner and Frazier, 1930) . After a follow-up study of the Gardner and Frazier family in 1971, it was again concluded that this disorder was distinct from that described by von Recklinghausen and the separation of these two types of neurofibromatosis became widely accepted (Young et al., 1971) . The National Institutes of Health Consensus Statement on Neurofibromatosis in 1987 provided clear guidelines for the diagnosis of NF1 and NF2 (Table 1) . Linkage mapping of the gene for NF1 to the long arm of chromosome 17 (Barker et al., 1987) and of the NF2 gene to the long arm of chromosome 22 (Rouleau et al., 1987) unequivocally established that these two diseases were distinct. In 1991, the term ''acoustic neuroma'' was replaced with the more accurate pathological descriptor ''vestibular schwannoma' ' (Parry and Eldridge, 1991) .
Individuals affected with NF2 most commonly present with deafness, tinnitis (ringing in the ears), and vertigo (sensation of spinning or loss of balance) (Evans, 1992a; Mautner et al., 1996) . Other symptoms relate to the site or location of the tumors and include seizures, as well as weakness, muscle wasting, and root pain in the distribution of nerves impacted upon Neurobiology of Disease 3, 247-261 (1997) Article No. NB970128
